Acadian Asset Management LLC decreased its stake in shares of China Cord Blood Corp (NYSE:CO) by 26.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 69,211 shares of the medical research company’s stock after selling 25,283 shares during the period. Acadian Asset Management LLC owned about 0.06% of China Cord Blood worth $689,000 at the end of the most recent reporting period.
A number of other hedge funds have also made changes to their positions in CO. Ameriprise Financial Inc. purchased a new stake in shares of China Cord Blood in the third quarter worth $3,881,000. Parametrica Management Ltd boosted its position in shares of China Cord Blood by 1,842.1% during the third quarter. Parametrica Management Ltd now owns 304,903 shares of the medical research company’s stock worth $3,391,000 after acquiring an additional 289,203 shares during the last quarter. Wells Fargo & Company MN boosted its position in shares of China Cord Blood by 1,260,105.6% during the third quarter. Wells Fargo & Company MN now owns 226,837 shares of the medical research company’s stock worth $2,522,000 after acquiring an additional 226,819 shares during the last quarter. SG Americas Securities LLC boosted its position in shares of China Cord Blood by 131.2% during the third quarter. SG Americas Securities LLC now owns 231,204 shares of the medical research company’s stock worth $2,571,000 after acquiring an additional 131,204 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new position in shares of China Cord Blood during the third quarter worth $944,000. 8.63% of the stock is owned by institutional investors and hedge funds.
China Cord Blood Corp (NYSE CO) opened at $10.52 on Friday. The company has a market cap of $1,292.88, a price-to-earnings ratio of 30.06 and a beta of 0.91. China Cord Blood Corp has a 12-month low of $5.06 and a 12-month high of $14.95.
China Cord Blood (NYSE:CO) last posted its quarterly earnings results on Monday, November 20th. The medical research company reported $0.09 EPS for the quarter. China Cord Blood had a net margin of 26.79% and a return on equity of 9.68%. The company had revenue of $35.26 million for the quarter.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/18/china-cord-blood-corp-co-position-trimmed-by-acadian-asset-management-llc.html.
China Cord Blood Company Profile
China Cord Blood Corporation is a provider of cord blood banking services in China. The Company and its subsidiaries are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China. It provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee.
Receive News & Ratings for China Cord Blood Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Cord Blood and related companies with MarketBeat.com's FREE daily email newsletter.